CEACAM5 and neoplasm: Moreover, lactate dehydrogenase (LDH) or peripheral blood tumor marker carcinoembryonic antigen (CEA) might also be a reliable biomarker to predict immunotherapy efficacy in NSCLC patients (56–58).